 | | Vol. 14.08 – 28 February, 2023 |
| |
|
|
| Researchers identified ubiquitin-conjugating enzyme E2T (UBE2T) as a potential therapeutic target to combat gemcitabine resistance in pancreatic cancer.
[Gastroenterology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Both global and β-cell-specific Thada-knockout mice exhibited improved glycemic control owing to enhanced β-cell function and decreased β-cell apoptosis.
[Nature Communications] |
|
|
|
| An experimental pancreatitis was induced in C57BL/6J, Ripk3-/- and mixed-lineage kinase domain-like protein-/- (Mlk-/-) mice by cerulein plus lipopolysaccharide in vivo, and primary pancreatic acinar cells were also isolated to uncover cellular mechanisms during cerulein stimulation in vitro.
[Cell Death & Disease] |
|
|
|
| The authors explored the regulatory role of metastasis associated lung adenocarcinoma transcript 1 (MALAT1) in gastrointestinal motility dysfunction following severe acute pancreatitis.
[Molecular Immunology] |
| |
|
|
| Researchers leveraged a hyperactive p53 variant which was previously showed as a more robust PDAC suppressor than wild-type p53, to elucidate how p53 acted at the cellular level to dampen PDAC development.
[Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| Scientists used a lineage-traced sporadic model of pancreatic cancer to generate a murine organoid biobank from primary and secondary tumors, including sublines that underwent partial epithelial-mesenchymal transition (EMT) and complete EMT.
[Cell Death & Differentiation] |
|
|
|
| In primary and immortalized pancreatic cancer cells, shRNA-induced matrix remodeling associated 5 (MXRA5) silencing or CRISPR/Cas9-mediated MXRA5 knockout suppressed cell survival, proliferation, migration, invasion, and epithelial-mesenchymal transition, while provoking cell apoptosis.
[Cell Death & Disease] |
|
|
|
| Using the KrasG12D-based mouse model of human PDAC, investigators found that ablating Prdm16 did not block but instead accelerated PDAC formation and progression, suggesting that Prdm16 might function as a tumor suppressor in this malignancy.
[Journal of Cell Biology] |
|
|
|
| Scientists explored the role of hepatocyte nuclear factor 1 homeobox A (HNF1A) in oxaliplatin resistance in PDAC and revealed that HNF1A expression was negatively associated with oxaliplatin chemoresistance in PDAC tissues and cell lines.
[International Journal of Oncology] |
|
|
|
|
| Investigators review the most current findings on the role of hypoxia and HGF/c-MET expression in the treatment of pancreatic cancer.
[Biochimica Et Biophysica Acta-Reviews On Cancer] |
|
|
|
|
| TransCode Therapeutics, Inc. announced that it has received Orphan Drug Designation from the US FDA for its lead therapeutic candidate, TTX-MC138, in pancreatic cancer.
[TransCode Therapeutics, Inc.] |
|
|
|
|
| April 17 – 19, 2023
Freiburg im Breisgau, Germany |
|
|
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | University of Missouri – Columbia, Missouri, United States |
|
|
|
| | University of Minnesota – Minneapolis, Minnesota, United States |
|
|
|
| | The Henry Ford Health System – Detroit, Michigan, United States |
|
|
|
| | University of Gothenburg – Gothenburg, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
